24 November 2025 Sydney, Australia

Notice of Initial Substantial Security Holder ("Notice")

Nyrada Inc (ASX: NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests ("CDIs"), a Notice of Initial Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder: Matt Corp WA Pty Ltd

Date of becoming a Substantial Holder: 20 November 2025

Details of voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):

Class of Securities	Number of CDIs	Person's Votes	Voting Power (1)
Chess Depository Interests	12,273,580	12,273,580	5.12%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
Matt Corp WA Pty Ltd	Matt Corp WA Pty Ltd	12,028,580	5.02%
Jubec Pty Ltd	Jubec Pty Ltd	245,000	0.10%

(1) Based on 239,783,704 CDIs on issue on issue as outlined in Appendix 2A released to ASX on 13 November 2025.

NYR has provided a copy of this Notice to Matt Corp WA Pty Ltd who have confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) (Act), including the number of equity securities or CDIs disclosed in the Notice, being 12,273,580 CDIs, and that these equity securities represent all equity securities held, and to be held under legal agreement, by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.

– ENDS –

About Nyrada Inc

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

Investor, Media & Corporate Enquiries:
Dimitri Burshtein
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.